<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="266">
  <stage>Registered</stage>
  <submitdate>10/08/2001</submitdate>
  <approvaldate>10/08/2001</approvaldate>
  <nctid>NCT00022451</nctid>
  <trial_identification>
    <studytitle>Tipifarnib in Treating Young Patients With Refractory Leukemia</studytitle>
    <scientifictitle>A Phase I Trial and Pharmacokinetic Study of R115777 in Pediatric Patients With Refractory Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>01-C-0196C</secondaryid>
    <secondaryid>010196</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - tipifarnib

Treatment: drugs: tipifarnib


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed acute lymphoblastic leukemia, acute nonlymphoblastic
             leukemia, juvenile myelomonocytic leukemia (JMML), or chronic myelogenous leukemia
             (CML) in blast crisis

               -  Refractory to standard curative therapy

               -  Acute promyelocytic leukemia refractory to tretinoin and arsenic trioxide

               -  Philadelphia chromosome-positive CML refractory to imatinib mesylate

          -  Greater than 25% blasts in bone marrow (M3 bone marrow) except for patients with JMML

          -  Active extramedullary disease allowed

          -  No active leptomeningeal leukemia

        PATIENT CHARACTERISTICS:

        Age:

          -  21 and under

        Performance status:

          -  Karnofsky 50-100% (over 10 years of age)

          -  Lansky 50-100% (10 years of age and under)

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not required to be normal

        Hepatic:

          -  Bilirubin normal

          -  SGPT and SGOT normal

          -  No significant hepatic dysfunction

          -  No grade 3 or 4 liver function test results within the past month

        Renal:

          -  Creatinine normal OR

          -  Creatinine clearance at least 60 mL/min

          -  No significant renal dysfunction

        Cardiovascular:

          -  No significant cardiac dysfunction

        Pulmonary:

          -  No significant pulmonary dysfunction

        Neurologic:

          -  No history of grand mal seizures grade 3 or greater except febrile seizures

          -  No persistent sensory or motor neuropathy greater than grade 2

        Other:

          -  No clinically significant unrelated systemic illness

          -  No serious infection

          -  No organ dysfunction that would preclude study participation

          -  No requirement for total parenteral nutrition

          -  No known allergy to azoles (e.g., clotrimazole, fluconazole, ketoconazole,
             voriconazole)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 1 week since prior colony-stimulating factor therapy (e.g., filgrastim
             [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa

          -  At least 3 months since prior myeloablative therapy followed by bone marrow or stem
             cell transplantation

          -  No concurrent immunotherapy

          -  No concurrent GM-CSF or interleukin-11

        Chemotherapy:

          -  At least 2 weeks since prior chemotherapy

          -  No concurrent intrathecal chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  At least 1 week since prior corticosteroids

          -  No concurrent corticosteroids (except for acute allergic reaction)

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  Recovered from nonhematologic toxicity of all prior therapy

          -  At least 1 week since prior retinoids

          -  No antacids (magnesium- or aluminum-containing formulations) within 2 hours of study
             drug

          -  No other concurrent investigational agents

          -  No concurrent retinoids

          -  No concurrent anticonvulsants</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC,WA</recruitmentstate>
    <hospital>Royal Children's Hospital - Parkville</hospital>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>3052 - Parkville</postcode>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Institutes of Health Clinical Center (CC)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Children's Oncology Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary
      for cancer cell growth.

      PURPOSE: Phase I trial to study the effectiveness of tipifarnib in treating young patients
      who have refractory leukemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00022451</trialwebsite>
    <publication>de Nigris F, Balestrieri ML, Napoli C. Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders. Cell Cycle. 2006 Aug;5(15):1621-8. Epub 2006 Aug 1. Review.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Brigitte C. Widemann, MD</name>
      <address>National Cancer Institute (NCI)</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>